Table 3.
Subgroup analysis for risk of outcomes associated with switchers vs. non-switchers in patients with cancer-associated venous thrombosis in six months
| Subgroups | Non-Switchers (N) | Switchers (N) | Hospitalization due to VTE | Major bleeding | All-cause mortality | ||||
|---|---|---|---|---|---|---|---|---|---|
| Adjusted Hazard Ratio (95% CI) | P value | Adjusted Hazard Ratio (95% CI) | P value | Adjusted Hazard Ratio (95% CI) | P value | ||||
| Sex | Male | 1236 | 739 | 0.51 (0.32–0.82) | 0.005 | 0.91 (0.65–1.27) | 0.563 | 0.67 (0.58–0.76) | 5.08e-9 |
| Female | 1420 | 961 | 0.49 (0.31–0.77) | 0.002 | 1.20 (0.88–1.64) | 0.256 | 0.69 (0.61–0.78) | 2.21e-9 | |
| Age | < = 65 years | 1274 | 764 | 0.51 (0.32–0.82) | 0.006 | 0.83 (0.58–1.18) | 0.294 | 0.72 (0.62–0.83) | 3.99e-6 |
| >65 years | 1382 | 936 | 0.46 (0.30–0.72) | 7.11e-4 | 1.22 (0.90–1.65) | 0.198 | 0.64 (0.57–0.73) | 1.28e-12 | |
| Metastasis | No | 1528 | 1009 | 0.58 (0.40–0.86) | 0.006 | 1.23 (0.91–1.67) | 0.178 | 0.60 (0.53–0.69) | 2.11e-14 |
| Yes | 1128 | 691 | 0.33 (0.17–0.63) | 7.42e-4 | 0.87 (0.62–1.23) | 0.438 | 0.77 (0.67–0.87) | 5.95e-5 | |
| Gastrointestinal malignancy | No | 1883 | 1253 | 0.49 (0.33–0.70) | 1.43e-4 | 1.08 (0.84–1.40) | 0.552 | 0.66 (0.59–0.74) | 1.40e-13 |
| Yes | 773 | 447 | 0.51 (0.26–1.00) | 0.052 | 0.90 (0.55–1.49) | 0.692 | 0.72 (0.61–0.85) | 1.12e-4 | |
| Platinum treatment within 3 months before index date | No | 2296 | 1453 | 0.46 (0.32–0.65) | 1.06e-5 | 1.09 (0.85–1.39) | 0.507 | 0.65 (0.59–0.71) | 4.40e-18 |
| Yes | 360 | 247 | 0.79 (0.33–1.89) | 0.600 | 0.85 (0.46-–1.55) | 0.589 | 0.89 (0.70–1.13) | 0.351 | |
| CCI | Low ( < 6) | 1108 | 677 | 0.59 (0.35–0.98) | 0.042 | 1.25 (0.87–1.81) | 0.231 | 0.62 (0.53–0.72) | 2.25e-9 |
| High (> = 6) | 1548 | 1023 | 0.42 (0.27–0.64) | 5.06e-5 | 0.93 (0.69–1.25) | 0.628 | 0.71 (0.64–0.80) | 3.80e-9 | |
| Khorana risk score | Low ( < 2) | 1049 | 809 | 0.49 (0.31–0.79) | 0.003 | 1.11 (0.78–1.60) | 0.557 | 0.67 (0.57–0.78) | 1.22e-7 |
| High (>=2) | 1607 | 891 | 0.45 (0.29–0.71) | 6.46e-4 | 1.01 (0.75–1.37) | 0.955 | 0.68 (0.61–0.77) | 1.95e-10 | |
| Bleeding risk | Low | 718 | 517 | 0.44 (0.23–0.84) | 0.013 | 1.68 (1.06–2.65) | 0.026 | 0.57 (0.48–0.69) | 5.97e-9 |
| High | 1938 | 1183 | 0.50 (0.34–0.72) | 2.44e-4 | 0.91 (0.70–1.19) | 0.486 | 0.71 (0.64–0.79) | 1.74e-10 | |
| Treatment duration before switching | Shorter (< = 10 days) | 2656 | 935 | 0.57 (0.38–0.85) | 0.007 | 1.06 (0.80–1.41) | 0.673 | 0.72 (0.64–0.81) | 3.04e-8 |
| Longer ( > 10 days) | 2656 | 765 | 0.37 (0.22–0.60) | 6.39e-5 | 1.06 (0.77–1.47) | 0.704 | 0.64 (0.56–0.74) | 3.70e-10 | |
N Number of patients, CI Confidence interval, VTE Venous thromboembolism, CCI Charlson comorbidity index. All P values were from 2-sided tests and results were deemed statistically significant at P < 0.05.